VYNE Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	0.42	0.48	0.93	20.99	0.44	3.6	4.58	0.67	0
Revenue Growth (YoY)	-11.11%	-48.76%	-95.57%	4638.83%	-87.68%	-21.54%	579.82%	-	-
Cost of Revenue	0	0	0	1.39	0	0	0	0	0
Gross Profit	0.42	0.48	0.93	19.6	0.44	3.6	4.58	0.67	0
Selling, General & Admin	13.38	16.39	20.3	89.54	45.11	14.01	5.17	3.75	1.69
Research & Development	16.31	18.39	19.54	43.53	51.2	64.47	29.01	11.26	2.92
Other Operating Expenses	0	0	0	139.07	0	0	0	0	0
Operating Expenses	29.68	34.77	39.84	272.15	96.32	78.49	34.18	15.01	4.61
Operating Income	-29.26	-34.3	-38.91	-252.55	-95.87	-74.89	-29.59	-14.33	-4.61
Interest Expense / Income	0	0	5.61	4.39	0.92	0	-0.52	-0.26	0
Other Expense / Income	-0.81	-11.1	29.26	-1.11	-1.44	-0.94	-	-	-
Pretax Income	-28.45	-23.2	-73.78	-255.83	-95.35	-73.95	-29.08	-14.07	-4.61
Income Tax	0	0.01	-0.45	-0.26	-0.18	0.21	0	0	0
Net Income	-28.45	-23.21	-73.33	-255.57	-95.18	-74.16	-29.08	-14.07	-4.61
Shares Outstanding (Basic)	10	3	3	2	0	0	0	0	0
Shares Outstanding (Diluted)	10	3	3	2	0	0	0	0	0
Shares Change	222.44%	11.44%	58.75%	282.06%	31.22%	406.33%	2.43%	5.32%	-
EPS (Basic)	-2.78	-7.28	-25.64	-141.84	-201.96	-206.46	-409.68	-203.04	-69.84
EPS (Diluted)	-2.78	-7.28	-25.64	-141.84	-201.96	-206.46	-409.68	-203.04	-69.84
Free Cash Flow	-25.34	-29.2	-56.37	-137.2	-74.41	-69.22	-28.25	-2.3	-4.18
Free Cash Flow Per Share	-2.47	-9.16	-19.72	-76.18	-157.86	-192.70	-398.18	-33.15	-63.60
Gross Margin	100.00%	100.00%	100.00%	93.37%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-6900.47%	-7189.73%	-4179.48%	-1203.00%	-21641.76%	-2083.23%	-645.85%	-2126.41%	-
Profit Margin	-6710.38%	-4865.83%	-7876.37%	-1217.40%	-21484.88%	-2062.95%	-634.57%	-2087.24%	-
Free Cash Flow Margin	-5976.65%	-6121.59%	-6054.46%	-653.53%	-16797.29%	-1925.48%	-616.52%	-340.65%	-
EBITDA	-28.45	-23.13	-68.06	-251.1	-94.08	-73.63	-29.59	-14.33	-4.61
EBITDA Margin	-6710.38%	-4848.01%	-7310.20%	-1196.09%	-21237.70%	-2048.18%	-645.68%	-2125.82%	-
Depreciation & Amortization	0	0.07	0.11	0.34	0.35	0.32	0.01	0	0
EBIT	-28.45	-23.2	-68.17	-251.44	-94.43	-73.95	-29.59	-14.33	-4.61
EBIT Margin	-6710.38%	-4863.10%	-7321.91%	-1197.71%	-21316.70%	-2057.05%	-645.85%	-2126.41%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).